Cushing's disease

Standlee® Unveils Smart Carb™ Performance and Forage Plus™ Gastric Support

Retrieved on: 
Thursday, January 18, 2024
Syndrome, Digestion, Insulin resistance, Animal, Health, Molasses, Alfalfa, Disease, Risk, Tropical ulcer, Leaky gut syndrome, Forage, Horse, Starch, Probiotic, Cushing's disease, Intake, Teff, Marketing

KIMBERLY, Idaho, Jan. 18, 2024 /PRNewswire/ -- In a stride towards innovation, Standlee proudly expands its forage-first product offerings with the introduction of Smart Carb™ Performance and Forage Plus™ Gastric Support. Formulated by Dr. Stephen Duren, Ph.D., Equine Nutritionist at Standlee, these blended forage-based pellets are carefully crafted to meet the unique nutritional needs of horses.

Key Points: 
  • Standlee Unveils Smart Carb Performance & Forage Plus Gastric Support: Elevating Equine Nutrition with Forage Blends
    "We are committed to meeting our customers' and their animals' needs, through innovation," said Scott Plew, President of Standlee Premium Products, LLC.
  • Designed to meet consumer demands, Smart Carb & Forage Plus pellets stand out as the perfect supplement for a range of forages.
  • Forage Plus Gastric Support is formulated to buffer stomach acid, support digestive tissue health, and promote a healthy gut microbiome.
  • Standlee continues to prioritize your horse's health and nutritional requirements through innovated products Smart Carb Performance and Forage Plus Gastric Support is available for retailers to order.

Groundbreaking DNA Test Gives Dog Owners Closure on Deceased Pets

Retrieved on: 
Wednesday, April 5, 2023
Cushing's disease, DNA, Partnership, Bed, Lab, Parent, Pet, Lakehead University, Dog, Master, Death, Family, Test management, Vaccine

TORONTO, April 5, 2023 /PRNewswire-PRWeb/ -- A cutting-edge, one-of-a-kind DNA test is finally giving some dog owners closure on pets that have died – even as long as over a decade ago.

Key Points: 
  • Canine DNA testing company DNA My Dog shares cutting-edge, one-of-a-kind DNA test that is finally giving dog owners closure on pets that have died – even as long as over a decade ago.
  • TORONTO, April 5, 2023 /PRNewswire-PRWeb/ -- A cutting-edge, one-of-a-kind DNA test is finally giving some dog owners closure on pets that have died – even as long as over a decade ago.
  • The test – the only deceased dog DNA testing service in the world - is available through a partnership between Toronto-based canine DNA testing company DNA My Dog and the Paleo-DNA Lab at Lakehead University in Ontario.
  • "I found DNA My Dog's deceased DNA Test and decided to send Tigger's favorite stuffed toy in to be tested.

Target RWE Launches 35 New Disease State Registries in Complex Indications with High Unmet Medical Needs and Rapidly Evolving Therapies

Retrieved on: 
Wednesday, January 11, 2023
Degenerative disease, Alopecia areata, Hidradenitis suppurativa, Disease, Vitiligo, Atopic dermatitis, Entrepreneurship, Immunology, Publication, Lupus, Natural history, Public health, Chief Medical Advisor to the President, Psoriatic arthritis, Icahn School of Medicine at Mount Sinai, Cushing's disease, Safety, Ankylosing spondylitis, RWD, Psoriasis, Plasma, RWE, Diabetes, Patient, Research, Serum, Target, Mount Sinai, Acquisition, Non-alcoholic fatty liver disease, Doctor of Philosophy, NASH, Rheumatoid arthritis, Registry, Pharmaceutical industry, Dermatology, Kidney, Gastroenterology, Obesity

DURHAM, N.C., Jan. 11, 2023 /PRNewswire/ -- Target RWE, the leader and largest provider of real-world evidence (RWE) in non-cancer conditions, announced today the launch of 35 new observational disease state registries, including, TARGET-AUTOIMMUNE, TARGET-NEURO and TARGET-METABOLIC. Additional disease state registries launched today include Kidney (TARGET-KIDNEY) and Gastroenterology (TARGET-GASTRO), and an expansion of its existing Liver community.

Key Points: 
  • Additional disease state registries launched today include Kidney (TARGET-KIDNEY) and Gastroenterology (TARGET-GASTRO), and an expansion of its existing Liver community.
  • The TARGET-NEURO and TARGET-METABOLIC registries capture real-world patient data in high unmet need disease states such as Alzheimer's Disease/ Related Dementias, Obesity, Cushing's Disease, Diabetes and Nonalcoholic Steatohepatitis (NASH).
  • Meaningful real-world research considers all of these complexities," said Michael W. Fried, M.D., FAASLD, Co-Founder and Chief Medical Officer, Target RWE.
  • Follow Target RWE on LinkedIn and Twitter to keep up with the latest on our new communities and other company news.

Global Endocrine Testing Market Report 2022: Development of Innovative Easy-To-Operate Test Kits to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 14, 2022
Biotechnology, Health, Other Health, Gigantism, Laboratory, COVID-19, Prevalence, Adrenal insufficiency, Hypothyroidism, Patient, Coronavirus, LC-MS, Cushing's disease, Health care, Hyperthyroidism, Awareness, Mass spectrometry, Hyperglycemia, CAGR, Pharmaceutical industry, Growth

The "Endocrine Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Endocrine Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global endocrine testing market size reached US$ 9.7 Billion in 2021.
  • Furthermore, the increasing health consciousness and awareness regarding the benefits of timely testing is providing a boost to the market growth.
  • Additionally, the development of innovative easy-to-operate test kits equipped with biosensors that facilitate user-friendly and cost-effective home-based diagnosis is creating a positive outlook for the market.

Recordati Rare Diseases Announce Publication of Long-term Outcomes From the Extension to the Phase III LINC 3 Study of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease in the European Journal of Endocrinology

Retrieved on: 
Wednesday, August 31, 2022
Research, Managed Care, General Health, Pharmaceutical, Oncology, Hospitals, Science, Surgery, Cardiology, Nursing, Health, Diabetes, Consensus, AES, Safety, Research, Hirsutism, Guru Angad Dev Veterinary and Animal Sciences University, Conditional sentence, Maintenance, Adrenocorticotropic hormone, CYP11B1, Meta-analysis, Osilodrostat, European Journal, Cushing's syndrome, Adult, Endocrinology, Risk, Patient, ISIN, Female, Degenerative disease, OR, Disorder, Manuscript, Oregon Health Plan, Consensus decision-making, Advertising, Pituitary adenoma, EMEA, Reuters, Rare, Neurosurgery, David Ferrier, Quality of life, LINC, Cushing's disease, European Commission, Marketing, Nature, Microdeletion syndrome, Oregon Health & Science University, Phase, Royal commission, Manchester, ULN, The Lancet, III, Uncertainty, Pharmaceutical industry, Silviculture, EU, Diagnosis

Median duration of exposure to Isturisa from core study baseline to end of the extension was 130 weeks (range 1245).

Key Points: 
  • Median duration of exposure to Isturisa from core study baseline to end of the extension was 130 weeks (range 1245).
  • Recordati Rare Diseases is committed to improving the lives of patients with this rare, debilitating and life-threatening condition.
  • Long-term outcomes of osilodrostat in Cushings disease: LINC 3 study extension The European Journal of Endocrinology 2022.
  • Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.

Popular Veterinary Career Site and Continuing Education Provider Launch New Content Partnership

Retrieved on: 
Thursday, July 28, 2022
University, Licensure, Education, Cushing's disease, American College, RACE, Journal of Veterinary Internal Medicine, Student, CEO, Social media, Registry, Disease, Partnership, Ownership, Tuskegee University, COVID-19, PETS, Organization, Ageing, MBA, American Veterinary Medical Association, Patient, Diabetes, DVM, Internal medicine, Endocrinology, Addison's disease, Candy, Veterinary medicine, Medicine, Dog

WAUKESHA, Wis., July 28, 2022 /PRNewswire/ -- Vetcetera, an online community for professional development and education for veterinary professionals and students, and Vet Candy, a veterinary news source and continuing education provider, today announced a new partnership that will expand access to continuing education for practicing veterinarians. This partnership provides informative and high quality content that both entertains and educates.

Key Points: 
  • WAUKESHA, Wis., July 28, 2022 /PRNewswire/ -- Vetcetera, an online community for professional development and education for veterinary professionals and students, and Vet Candy, a veterinary news source and continuing education provider, today announced a new partnership that will expand access to continuing education for practicing veterinarians.
  • Due to limited access to in-person continuing education during COVID-19, online veterinary continuing education options have become increasingly popular.
  • To help meet the growing demand for veterinary care, the two organizations will collaborate to create and deliver continuing education courses that qualify for approval by the Registry of Approved Continuing Education (RACE).
  • "By bringing high-quality continuing education content to this popular online community, veterinary pros will receive the engaging content they need to support their full career trajectory from student to practitioner."

Global Cushing Syndrome Drug Pipeline Market Research Report 2022: Comprehensive Insights About 8+ Companies and 8+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 25, 2022
Health, Pharmaceutical, Company, Cushing's disease, Glucose, II, Congenital adrenal hyperplasia, Disease, Patient, Mergers and acquisitions, Liver, SAD, Trial of the century, CAH, ACTH, Triglyceride, Cholesterol, Safety, Technology, Union, NDA, Therapy, Pancreatic cancer, Acquisition, Glycated hemoglobin, Oil, Pharmaceutical industry, Cushing's syndrome

This "Cushing Syndrome - Pipeline Insight, 2022" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Cushing Syndrome pipeline landscape.

Key Points: 
  • This "Cushing Syndrome - Pipeline Insight, 2022" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Cushing Syndrome pipeline landscape.
  • A detailed picture of the Cushing Syndrome pipeline landscape is provided which includes the disease overview and Cushing Syndrome treatment guidelines.
  • The assessment part of the report embraces, in depth Cushing Syndrome commercial assessment and clinical assessment of the pipeline products under development.
  • This segment of the report provides insights about the different Cushing Syndrome drugs segregated based on following parameters that define the scope of the report.

Phase III LINC 3 Study Demonstrates That ISTURISA® (osilodrostat) Improves Physical Features Associated With Hypercortisolism in Patients With Cushing’s Disease

Retrieved on: 
Friday, May 13, 2022
Health, Pharmaceutical, Abdominal pain, Hypokalemia, Lactation, Infection, Magnesium, Hypotension, Mortality, Androgen, Plasma, Osilodrostat, Manchester, Week, Risk, American Association, Headache, Pituitary adenoma, Fatigue, Edema, Medical Affairs Bureau, Serum, Nausea, Cushing's disease, AACE, Arrhythmia, Incidence, Symptoms of COVID-19, Hirsutism, Hypoglycemia, The Lancet, Phase, Quality of life, Nature, Degenerative disease, Research, ACTH, III, Vomiting, Advertising, QT interval, ECG, Dizziness, Adrenal insufficiency, Waist, Uncertainty, Health, Association, Half-life, CYP3A4, Adult, FDA, Hyperandrogenism, Awareness, De novo, CYP2B6, Disease, QT, Microdeletion syndrome, Safety, LINC, Diagnosis, Hypertension, Pharmaceutical industry, Medical imaging, Birth control, Patient

Recordati Rare Diseases Inc. announced today that the Phase III LINC 3 study demonstrates ISTURISA (osilodrostat) improves physical features associated with hypercortisolism in patients with Cushings disease.

Key Points: 
  • Recordati Rare Diseases Inc. announced today that the Phase III LINC 3 study demonstrates ISTURISA (osilodrostat) improves physical features associated with hypercortisolism in patients with Cushings disease.
  • Patients with Cushings disease experience multiple physical manifestations of hypercortisolism that may reduce quality of life.
  • According to the abstract entitled Osilodrostat Therapy Improves Physical Features Associated with Hypercortisolism in Patients with Cushings Disease: Findings from the Phase III LINC 3 Study, 137 adult Cushings disease patients with mUFC >1.5 x the upper limit of normal were enrolled in the 48-week core phase to evaluate the safety and efficacy of ISTURISA in patients with Cushings disease.
  • Changes to physical features caused by Cushings disease can have a significant impact on patient health and well-being.

Global Cushing's Syndrome Diagnostic and Treatment Market Research Report 2022-2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 27, 2022
Health, Pharmaceutical, Adoption, Cushing's disease, Association, Adult, Weight gain, American Association of Neurological Surgeons, Incidence, Hyperlipidemia, Hospital, Novartis, Patient, Adenoma, Growth, Cushing's syndrome, Neoplasm, Review, Pituitary gland, Skin, Method, Adrenocorticotropic hormone, Blood, Safety, American Association, Union, FDA, PGI, Prevalence, Disease, Exocrine gland, ACTH, Oil, Pharmaceutical industry

The "Cushing's Syndrome Diagnostic And Treatment Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cushing's Syndrome Diagnostic And Treatment Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global cushing's syndrome diagnostic & treatment market is expected to grow at a compound annual growth rate of 8.94% over the forecast period to reach a market size of US$555.415 million in 2027, from US$305.004 million in 2020.
  • The market is expected to surge in the coming years, due to the rise in the number of Cushing syndrome cases, worldwide.
  • With the rise in the number of Cushing syndrome diseases, the demand for novel treatment and diagnostic solutions is expected to surge.

Winter's shorter days are here: Protect your bones

Retrieved on: 
Thursday, December 2, 2021
Research, Patient, Man, U.S. News & World Report, RDA, Skin, Degenerative disease, Cushing's disease, Sunlight, Sports medicine, MOR, Crohn's disease, Smoking, NIH, Exercise, News, Vitamin D, Woman, Tobacco, Chicago Fire FC, Joffrey Ballet, Inflammation, Bone density, Rickets, Recommended maximum intake of alcoholic beverages, Egg, Bone loss, Dairy, Ius, Physician, Cheese, Chicago White Sox, Milk, Joint, Rush University Medical Center, Absorption, Daylight saving time, UVB, Tuna, Walking, Park Ridge, Food, Munster, Jogging, Chicago Bulls, Chicago Bulls (AFL, 1926), No, Osteoporosis, Salmon, Osteopenia, Calcium, Dietary supplement

Whiledarker days can be emotionally hard, they can also be hazardous to your bones due to a lack of vitamin D and exercise.

Key Points: 
  • Whiledarker days can be emotionally hard, they can also be hazardous to your bones due to a lack of vitamin D and exercise.
  • According to a NIH study , the amount of vitamin D we obtain from the sun is limited during the winter.
  • Experts agree that incorporating the following tips can promote year-round bone health:
    Bone cells are continuously replaced, so it is important to consume calcium to keep bones strong.
  • Good sources of calcium include dairy products, almonds, broccoli, kale, canned salmon with bones, sardines, and soy products, such as tofu.